1 seventy-eight patients (52.4%) randomized to etelcalcetide achieved more than 50% reduction in PTH co

2 ge clinical trials to analyze the effects of etelcalcetide and cinacalcet to lower plasma PTH levels

3 49 and 384 pg/mL vs 820 and 897 pg/mL in the etelcalcetide and placebo groups, respectively, in trial

4 e efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet.

5 ary efficacy end point was noninferiority of etelcalcetide at achieving more than a 30% reduction fro

6 severe secondary hyperparathyroidism, use of etelcalcetide compared with placebo resulted in greater

7 ls A and B, respectively, patients receiving etelcalcetide had more muscle spasms (12.0% and 11.1% vs

8                                              Etelcalcetide intravenously and oral placebo (n = 340) o

9                Intravenous administration of etelcalcetide (n = 503) or placebo (n = 513) after each

10 e the effect of the intravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concent

11 ely during 26 weeks of treatment with either etelcalcetide or cinacalcet without regard to the degree

12 ve clinical trial was conducted comparing IV etelcalcetide vs oral placebo and oral cinacalcet vs IV

13 f 340 patients (68.2%) randomized to receive etelcalcetide was -10.5% (95% CI, -17.5% to -3.5%, P for

14                                              Etelcalcetide was noninferior to cinacalcet on the prima

15 re secondary hyperparathyroidism, the use of etelcalcetide was not inferior to cinacalcet in reducing

16                       Patients randomized to etelcalcetide were significantly more likely to achieve

17                       Patients randomized to etelcalcetide were significantly more likely to achieve